|
業務類別
|
-- |
|
業務概覽
|
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition include drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Meyers. |
| 公司地址
| 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123 |
| 電話號碼
| +86 51269566088 |
| 傳真號碼
| +86 51269566088 |
| 公司網頁
| https://www.innoventbio.com |
| 員工數量
| 5659 |
| Dr. De-Chao Michael Yu |
President, Chairman of the Board and Chief Executive Officer |
-- |
28/04/2025 |
|
|
| Dr. Charles Leland Cooney, PhD |
Independent Director |
28/04/2025 |
| Mr. Gary J. Zieziula |
Independent Director |
28/04/2025 |
| Ms. Qian Zhang |
Executive Director |
28/04/2025 |
| Mr. Shuyun Nick Chen |
Lead Independent Director |
28/04/2025 |
| Dr. De-Chao Michael Yu |
President, Chairman of the Board and Chief Executive Officer |
28/04/2025 |
| Mr. Hao Xi Ronald Ede |
Director |
28/04/2025 |
| Ms. I-Yin Joyce Hsu |
Independent Director |
28/04/2025 |
| Dr. Shun Lu |
Independent Director |
28/04/2025 |
|
|
|
|
